Wegovy® 1.7 mg is a once-weekly prescription injection in a single-dose prefilled pen containing semaglutide, a GLP-1 receptor agonist used for chronic weight management in adults with obesity or overweight conditions who have at least one weight-related medical condition. This dose is part of the stepwise dose-escalation phase, helping the body gradually adapt before reaching the maintenance dose.
Wegovy works by mimicking the natural GLP-1 hormone, which helps regulate appetite and food intake. It acts on appetite-control centers in the brain to significantly reduce hunger, decrease food cravings, and increase feelings of fullness after eating, supporting a lower calorie intake over time when combined with a reduced-calorie diet and increased physical activity.
The 1.7 mg single-dose pen is designed for subcutaneous injection once weekly, with each pen used for one dose only and then properly discarded after use. It is not intended for daily use.
Wegovy is intended for long-term medical weight management under healthcare supervision, and should be used exactly as prescribed as part of a structured treatment plan.
Common side effects may include:
- Nausea
- Vomiting
- Diarrhea or constipation
- Stomach pain or bloating
- Reduced appetite
- Fatigue in some users
These effects are often more noticeable during dose escalation as the body adjusts to treatment.
Always follow your healthcare provider’s instructions and injection guidance carefully.
Reviews
There are no reviews yet.